SPY413.31+0.45 0.11%
DIA338.81+2.02 0.60%
IXIC13,968.52-27.58 -0.20%

BRIEF-Relmada Therapeutics Announced Early Termination Of Ketamine Segment Of Human Abuse Potential Study Program On Rel-1017

· 03/15/2021 18:03
BRIEF-Relmada Therapeutics Announced Early Termination Of Ketamine Segment Of Human Abuse Potential Study Program On Rel-1017

- Relmada Therapeutics Inc RLMD.O:

  • RELMADA THERAPEUTICS INC - ANNOUNCED EARLY TERMINATION OF KETAMINE SEGMENT OF HUMAN ABUSE POTENTIAL STUDY PROGRAM ON REL-1017

  • RELMADA THERAPEUTICS INC - TERMINATION DUE TO FAILURE OF CONTROL DRUG ORAL KETAMINE 100MG TO SEPARATE FROM PLACEBO

Source: (https://bit.ly/3ljZLiw)

Further company coverage: RLMD.O


((Reuters.Briefs@thomsonreuters.com;))